Barclays analyst Carter Gould assigned a Buy rating to Regeneron (REGN – Research Report) today and set a price target of $1,080.00. The company’s shares closed last Friday at $933.02. According to ...
Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...
Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...
J.P. Morgan analyst Chris Schott maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,150.00.
REGNERON'S eighth annual “Day for Doing Good” was marked in Limerick and all over the world. It is a global volunteerism ...
On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), ...
Amgen pledges to launch Eylea biosim after legal win—but Regeneron stresses the fight's not over yet
While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based ...
CENTRAL TRUST Co lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.7% in ...
Two billion dollars in investments. 4,500 employees. Regeneron has grown into a major economic engine — and it's now ...
On Wednesday, Regeneron Pharmaceuticals Inc (REGN) stock saw a decline, ending the day at $941.39 which represents a decrease of $-20.95 or -2.18% from the prior close of $962.34. The stock opened at ...
Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) shareholders might be concerned after seeing the share price drop ...
Analysts expect the partners’ first-mover advantage, clinical data and existing presence in lung disease to translate into ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback